{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:59:31Z","timestamp":1793332771170,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR002379"],"award-info":[{"award-number":["KL2 TR002379"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR002379"],"award-info":[{"award-number":["KL2 TR002379"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD016450"],"award-info":[{"award-number":["S10OD016450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite advances in therapy for melanoma, heterogeneous responses with limited durability represent a major gap in treatment outcomes. The purpose of this study was to determine whether alteration in tumor blood flow could augment drug delivery and improve antitumor responses in a regional model of melanoma. This approach to altering tumor blood flow was termed \u201cdynamic control.\u201d Dynamic control of tumor vessels in C57BL\/6 mice bearing B16 melanoma was performed using volume expansion (saline bolus) followed by phenylephrine. Intravital microscopy (IVM) was used to observe changes directly in real time. Our approach restored blood flow in non-functional tumor vessels. It also resulted in increased chemotherapy (melphalan) activity, as measured by formation of DNA adducts. The combination of dynamic control and melphalan resulted in superior outcomes compared to melphalan alone (median time to event 40.0 vs 25.0\u00a0days, respectively, p\u2009=\u20090.041). Moreover, 25% (3\/12) of the mice treated with the combination approach showed complete tumor response. Importantly, dynamic control plus melphalan did not result in increased adverse events. In summary, we showed that dynamic control was feasible, directly observable, and augmented antitumor responses in a regional model of melanoma. Early clinical trials to determine the translational feasibility of dynamic control are ongoing.<\/jats:p>","DOI":"10.1038\/s41598-020-70233-5","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T10:04:51Z","timestamp":1596708291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Emmanuel M.","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay P.","family":"Bagaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Skitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"70233_CR1","unstructured":"SEER Cancer Statistics Factsheets: Melanoma of the Skin (National Cancer Institute, Bethesda MD). https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html. Accessed March 4, 2020."},{"key":"70233_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol.17, 1471\u20131474 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"70233_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","volume":"22","author":"RL Read","year":"2015","unstructured":"Read, R. L. et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann. Surg. Oncol.22, 475\u2013481 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"70233_CR4","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2005.20.537","volume":"23","author":"JC Kang","year":"2005","unstructured":"Kang, J. C. et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol.23, 4764\u20134770 (2005).","journal-title":"J Clin Oncol."},{"key":"70233_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","volume":"12","author":"TM Pawlik","year":"2005","unstructured":"Pawlik, T. M. et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann. Surg. Oncol.12, 587\u2013596 (2005).","journal-title":"Ann. Surg. Oncol."},{"key":"70233_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.amjsurg.2010.07.025","volume":"200","author":"CC Stucky","year":"2010","unstructured":"Stucky, C. C. et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am. J. Surg.200, 770\u2013774 (2010) (discussion 774\u2013775).","journal-title":"Am. J. Surg."},{"key":"70233_CR7","unstructured":"National Comprehensive Cancer Network. Melanoma (Version 2.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf. Accessed April 14, 2020."},{"key":"70233_CR8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/cancers7030830","volume":"7","author":"E Gabriel","year":"2015","unstructured":"Gabriel, E. & Skitzki, J. The role of regional therapies for in-transit melanoma in the era of improved systemic options. Cancers7, 1154\u20131177 (2015).","journal-title":"Cancers"},{"key":"70233_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.1964.03060360015003","volume":"188","author":"O Creech Jr","year":"1964","unstructured":"Creech, O. Jr. & Krementz, E. T. Regional perfusion in melanoma of limbs. JAMA188, 855\u2013858 (1964).","journal-title":"JAMA"},{"key":"70233_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/156802612798919187","volume":"12","author":"CL Defty","year":"2012","unstructured":"Defty, C. L. & Marsden, J. R. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. Curr. Top. Med. Chem.12, 53\u201360 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"70233_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jamcollsurg.2011.03.013","volume":"213","author":"AK Raymond","year":"2011","unstructured":"Raymond, A. K. et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J. Am. Coll. Surg.213, 306\u2013316 (2011).","journal-title":"J. Am. Coll. Surg."},{"key":"70233_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3109\/02656736.2013.802374","volume":"29","author":"R Olofsson","year":"2013","unstructured":"Olofsson, R., Mattsson, J. & Lindner, P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int. J. Hyperthermia.29, 551\u2013557 (2013).","journal-title":"Int. J. Hyperthermia."},{"key":"70233_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol.31, 2205\u20132218 (2013).","journal-title":"J. Clin. Oncol."},{"key":"70233_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc.2017.93","volume":"17","author":"MW Dewhirst","year":"2017","unstructured":"Dewhirst, M. W. & Secomb, T. W. Transport of drugs from blood vessels to tumour tissue. Nat. Rev. Cancer.17, 738\u2013750 (2017).","journal-title":"Nat. Rev. Cancer."},{"key":"70233_CR15","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan, V. P. et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun.4, 2516 (2013).","journal-title":"Nat. Commun."},{"key":"70233_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat Rev Cancer.6, 583\u2013592 (2006).","journal-title":"Nat Rev Cancer."},{"key":"70233_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1517\/17425247.5.2.205","volume":"5","author":"I Hamad","year":"2008","unstructured":"Hamad, I. & Moghimi, S. M. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opin. Drug Deliv.5, 205\u2013219 (2008).","journal-title":"Expert Opin. Drug Deliv."},{"key":"70233_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrc778","volume":"2","author":"RK Jain","year":"2002","unstructured":"Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer.2, 266\u2013276 (2002).","journal-title":"Nat. Rev. Cancer."},{"key":"70233_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/mvre.1994.1034","volume":"48","author":"I Lee","year":"1994","unstructured":"Lee, I., Demhartner, T. J., Boucher, Y., Jain, R. K. & Intaglietta, M. Effect of hemodilution and resuscitation on tumor interstitial fluid pressure, blood flow, and oxygenation. Microvasc. Res.48, 1\u201312 (1994).","journal-title":"Microvasc. Res."},{"key":"70233_CR20","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1126\/science.1071420","volume":"296","author":"TP Padera","year":"2002","unstructured":"Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science296, 1883\u20131886 (2002).","journal-title":"Science"},{"key":"70233_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1549-8719.2010.00029.x","volume":"17","author":"D Fukumura","year":"2010","unstructured":"Fukumura, D., Duda, D. G., Munn, L. L. & Jain, R. K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation17, 206\u2013225 (2010).","journal-title":"Microcirculation"},{"key":"70233_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1006\/mvre.1995.1069","volume":"50","author":"RA Zlotecki","year":"1995","unstructured":"Zlotecki, R. A., Baxter, L. T., Boucher, Y. & Jain, R. K. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc. Res.50, 429\u2013443 (1995).","journal-title":"Microvasc. Res."},{"key":"70233_CR23","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-11-3000","volume":"18","author":"RS Turley","year":"2012","unstructured":"Turley, R. S. et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin. Cancer Res.18, 3328\u20133339 (2012).","journal-title":"Clin. Cancer Res."},{"key":"70233_CR24","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI44952","volume":"121","author":"DT Fisher","year":"2011","unstructured":"Fisher, D. T. et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest.121, 3846\u20133859 (2011).","journal-title":"J. Clin. Invest."},{"key":"70233_CR25","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1038\/ncomms8458","volume":"6","author":"ME Mikucki","year":"2015","unstructured":"Mikucki, M. E. et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun.6, 7458 (2015).","journal-title":"Nat. Commun."},{"key":"70233_CR26","doi-asserted-by":"publisher","first-page":"6620","DOI":"10.1158\/0008-5472.CAN-15-2764","volume":"76","author":"M Kim","year":"2016","unstructured":"Kim, M. et al. Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas. Cancer Res.76, 6620\u20136630 (2016).","journal-title":"Cancer Res."},{"key":"70233_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1158\/0008-5472.CAN-05-3077","volume":"66","author":"R Grantab","year":"2006","unstructured":"Grantab, R., Sivananthan, S. & Tannock, I. F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res.66, 1033\u20131039 (2006).","journal-title":"Cancer Res."},{"key":"70233_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-2407-12-214","volume":"12","author":"RH Grantab","year":"2012","unstructured":"Grantab, R. H. & Tannock, I. F. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer.12, 214 (2012).","journal-title":"BMC Cancer."},{"key":"70233_CR29","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-05-2655","volume":"66","author":"J Hagendoorn","year":"2006","unstructured":"Hagendoorn, J. et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res.66, 3360\u20133364 (2006).","journal-title":"Cancer Res."},{"key":"70233_CR30","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1038\/ncomms10684","volume":"7","author":"DT Fisher","year":"2016","unstructured":"Fisher, D. T. et al. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat. Commun.7, 10684 (2016).","journal-title":"Nat. Commun."},{"key":"70233_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol.14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"70233_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"key":"70233_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science348, 74\u201380 (2015).","journal-title":"Science"},{"key":"70233_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpharm.2008.01.005","volume":"356","author":"D Yoshida","year":"2008","unstructured":"Yoshida, D., Todo, H., Hasegawa, T. & Sugibayashi, K. Effect of vasoactive agents on the dermatopharmacokinetics and systemic disposition of model compounds, salicylate and FITC-dextran 4 kDa, following intracutaneous injection of the compounds. Int. J. Pharm.356, 181\u2013186 (2008).","journal-title":"Int. J. Pharm."},{"key":"70233_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/02656730600738616","volume":"22","author":"TL ten Hagen","year":"2006","unstructured":"ten Hagen, T. L. & Eggermont, A. M. Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents. Int. J. Hyperthermia.22, 241\u2013246 (2006).","journal-title":"Int. J. Hyperthermia."},{"key":"70233_CR36","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1002\/ijc.30037","volume":"138","author":"A Graul-Conroy","year":"2016","unstructured":"Graul-Conroy, A., Hicks, E. J. & Fahl, W. E. Equivalent chemotherapy efficacy against leukemia in mice treated with topical vasoconstrictors to prevent cancer therapy side effects. Int. J. Cancer138, 3011\u20133019 (2016).","journal-title":"Int. J. Cancer"},{"key":"70233_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00685728","volume":"36","author":"NY Yu","year":"1995","unstructured":"Yu, N. Y., Orenberg, E. K., Luck, E. E. & Brown, D. M. Antitumor effect of intratumoral administration of fluorouracil\/epinephrine injectable gel in C3H mice. Cancer Chemother. Pharmacol.36, 27\u201334 (1995).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"70233_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/000348940411300312","volume":"113","author":"C Duvillard","year":"2004","unstructured":"Duvillard, C., Romanet, P., Cosmidis, A., Beaudouin, N. & Chauffert, B. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann. Otol. Rhinol. Laryngol.113, 229\u2013233 (2004).","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"70233_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archotol.128.8.880","volume":"128","author":"BL Wenig","year":"2002","unstructured":"Wenig, B. L. et al. The role of intratumoral therapy with cisplatin\/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg.128, 880\u2013885 (2002).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"70233_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.1991.118","volume":"63","author":"DM Hemingway","year":"1991","unstructured":"Hemingway, D. M., Cooke, T. G., Chang, D., Grime, S. J. & Jenkins, S. A. The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model of liver tumour. Br. J. Cancer.63, 495\u2013498 (1991).","journal-title":"Br. J. Cancer."},{"key":"70233_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bjc.1987.245","volume":"56","author":"MA Burton","year":"1987","unstructured":"Burton, M. A. & Gray, B. N. Redistribution of blood flow in experimental hepatic tumours with noradrenaline and propranolol. Br. J. Cancer.56, 585\u2013588 (1987).","journal-title":"Br. J. Cancer."},{"key":"70233_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00403-004-0488-x","volume":"296","author":"AC Scarparo","year":"2004","unstructured":"Scarparo, A. C. et al. Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors. Arch. Dermatol. Res.296, 112\u2013119 (2004).","journal-title":"Arch. Dermatol. Res."},{"key":"70233_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cbf.1309","volume":"24","author":"AC Scarparo","year":"2006","unstructured":"Scarparo, A. C., Visconti, M. A. & Castrucci, A. M. Signalling pathways evoked by alpha1-adrenoceptors in human melanoma cells. Cell Biochem. Funct.24, 119\u2013129 (2006).","journal-title":"Cell Biochem. Funct."},{"key":"70233_CR44","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","volume":"15","author":"HM Kroon","year":"2008","unstructured":"Kroon, H. M., Moncrieff, M., Kam, P. C. & Thompson, J. F. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann. Surg. Oncol.15, 3003\u20133013 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"70233_CR45","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/bjs.7621","volume":"98","author":"JP Deroose","year":"2011","unstructured":"Deroose, J. P. et al. Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br. J. Surg.98, 1573\u20131580 (2011).","journal-title":"Br. J. Surg."},{"key":"70233_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/jso.23552","volume":"109","author":"HJ Hoekstra","year":"2014","unstructured":"Hoekstra, H. J., Veerman, K. & van Ginkel, R. J. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?. J. Surg. Oncol.109, 338\u2013347 (2014).","journal-title":"J. Surg. Oncol."},{"key":"70233_CR47","unstructured":"Memorial Sloan Kettering Cancer Center. Addition of ipilimumab (MDX-010) to isolated limb infusion (ILI) with standard melphalan and dactinomycin in the treatment of advanced unresectable melanoma of the extremity. In: ClinicalTrials.gov. (National Library of Medicine (US), Bethesda (MD)). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01323517?term=NCT01323517&draw=2&rank=1. Accessed March 23, 2020."},{"key":"70233_CR48","doi-asserted-by":"publisher","first-page":"20165","DOI":"10.18632\/oncotarget.24957","volume":"9","author":"EM Gabriel","year":"2018","unstructured":"Gabriel, E. M., Fisher, D. T., Evans, S., Takabe, K. & Skitzki, J. J. Intravital microscopy in the study of the tumor microenvironment: from bench to human application. Oncotarget.9, 20165\u201320178 (2018).","journal-title":"Oncotarget."},{"key":"70233_CR49","unstructured":"Roswell Park Comprehensive Cancer Center. Intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy. In: ClinicalTrials.gov. (National Library of Medicine (US), Bethesda (MD)). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02857374?term=NCT02857374&draw=2&rank=1. Accessed March 23, 2020."},{"key":"70233_CR50","unstructured":"Mayo Clinic. Intravital microscopy (IVM) in patients with peritoneal carcinomatosis (PC). In: ClinicalTrials.gov (National Library of Medicine (US), Bethesda (MD)). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03517852?term=NCT03517852&draw=2& rank=1. Accessed March 23, 2020."},{"key":"70233_CR51","unstructured":"Roswell Park Comprehensive Cancer Center. Intravital microscopy in evaluating patients with primary peritoneal, Fallopian tube, or stage IA-IV ovarian cancer. In: ClinicalTrials.gov (National Library of Medicine (US), Bethesda (MD)) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03297489?term=NCT03297489&draw=2&rank=1. Accessed March 23, 2020."},{"key":"70233_CR52","unstructured":"Mayo Clinic. Intravital microscopy in human solid tumors. In: ClinicalTrials.gov. (National Library of Medicine (US), Bethesda (MD), 2020). https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT03823144&cntry=&state=&city=&dist=. Accessed March 23, 2020."},{"key":"70233_CR53","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s10439-008-9605-x","volume":"37","author":"H Wu","year":"2009","unstructured":"Wu, H., Exner, A. A., Krupka, T. M., Weinberg, B. D. & Haaga, J. R. Vasomodulation of tumor blood flow: effect on perfusion and thermal ablation size. Ann. Biomed. Eng.37, 552\u2013564 (2009).","journal-title":"Ann. Biomed. Eng."},{"key":"70233_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2253-13-15","volume":"13","author":"H Ruschulte","year":"2013","unstructured":"Ruschulte, H. et al. Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases. BMC Anesthesiol.13, 15 (2013).","journal-title":"BMC Anesthesiol."},{"key":"70233_CR55","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1245\/s10434-009-0563-9","volume":"16","author":"AA Santillan","year":"2009","unstructured":"Santillan, A. A. et al. Predictive factors of regional toxicity and serum creatine phospho-kinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann. Surg. Oncol.16, 2570\u20132578 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"70233_CR56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","volume":"208","author":"GM Beasley","year":"2009","unstructured":"Beasley, G. M. et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg.208, 706\u2013715 (2009) (discussion 715\u2013707).","journal-title":"J Am Coll Surg."},{"key":"70233_CR57","first-page":"1085","volume":"74","author":"SR Simon","year":"1985","unstructured":"Simon, S. R. & Ershler, W. B. Hormonal influences on growth of B16 murine melanoma. J. Natl. Cancer Inst.74, 1085\u20131088 (1985).","journal-title":"J. Natl. Cancer Inst."},{"key":"70233_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/08820130600745430","volume":"35","author":"DT Fisher","year":"2006","unstructured":"Fisher, D. T. et al. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol. Invest.35, 251\u2013277 (2006).","journal-title":"Immunol. Invest."},{"key":"70233_CR59","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1172\/JCI15598","volume":"111","author":"SP Heximer","year":"2003","unstructured":"Heximer, S. P. et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J. Clin. Investig.111, 445\u2013452 (2003).","journal-title":"J. Clin. Investig."},{"key":"70233_CR60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink, J., Benckhuysen, C., Braat, R. P., van Slooten, E. A. & Olthuis, G. A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur. J. Cancer18, 905\u2013910 (1982).","journal-title":"Eur. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70233-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70233-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70233-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:34:45Z","timestamp":1670340885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70233-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70233"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70233-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13245"}}